TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33130107

Group type: EXPERIMENTAL
Intervention: One Key Question (OKQ) intervention in primary care
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: One Key Question (OKQ) intervention in ob/gyn
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual care (control) in primary care
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual care (control) in ob/gyn
Number of subjects: 170
Study: 36064390

Group type: EXPERIMENTAL
Intervention: Intervention A with standardized compensation to the village doctors
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Intervention B with performance-based compensation to the village doctors
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Control without mobile-based knowledge dissemination
Number of subjects: 4000
Study: 32807267

Group type: EXPERIMENTAL
Intervention: Healive vaccine
Number of subjects: 375

Group type: COMPARATOR
Intervention: Havrix vaccine
Number of subjects: 375
Study: 35813442

Group type: EXPERIMENTAL
Intervention: PE+immunoglobulin
Number of subjects: 60

Group type: COMPARATOR
Intervention: PE
Number of subjects: 60
Study: 34597297

Group type: EXPERIMENTAL
Intervention: Na-GST-1 (30μg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Na-GST-1 (100μg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Na-APR-1
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (Hepatitis B)
Number of subjects: 24
Study: 35690697

Group type: EXPERIMENTAL
Intervention: RSP-TSS (Religious-Spiritual Psychotherapy based on the Twelver Shia Sects of Islam)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 45

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 45
Study: 33796993

Group type: EXPERIMENTAL
Intervention: Furosemide (0.05 to 0.4 mg/kg/h)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 75
Study: 34963186

Group type: EXPERIMENTAL
Intervention: Family history only (FH only)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Personal history only (PH only)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Both family and personal history (both FH/PH)
Number of subjects: 813

Group type: COMPARATOR
Intervention: No family/personal history (no FH/PH)
Number of subjects: 813
Study: 33301221

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) 13.8 g (two doses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bisacodyl 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 35112176

Group type: EXPERIMENTAL
Intervention: Posterior-to-anterior femoral tunnel aperture position parallel to Blumensaat line
Number of subjects: 78

Group type: COMPARATOR
Intervention: Tunnel aperture positions
Number of subjects: 78
Study: 33765513

Group type: COMPARATOR
Intervention: lapatinib + trastuzumab (L+T)
Number of subjects: 8381

Group type: COMPARATOR
Intervention: trastuzumab followed by lapatinib (T→L)
Number of subjects: 8381

Group type: EXPERIMENTAL
Intervention: trastuzumab (T)
Number of subjects: 8381
Study: 32462799

Group type: EXPERIMENTAL
Intervention: Radiomic signature model
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Radiomic model combining radiomic signature and clinicoradiologic characteristics
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Radiomic model
Number of subjects: 379
Study: 35142091

Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Standard oncology care
Number of subjects: 461
Study: 33284639

Group type: EXPERIMENTAL
Intervention: IBD-Home + standard care
Number of subjects: 158

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 158
Study: 35285241

Group type: EXPERIMENTAL
Intervention: Sutezolid 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sutezolid 600 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sutezolid 1200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sutezolid 1800 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sutezolid (all doses)
Number of subjects: 0
Study: 33154022

Group type: EXPERIMENTAL
Intervention: Trastuzumab alone
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus lapatinib
Number of subjects: 404

Group type: COMPARATOR
Intervention: Group A (DDFS event <12 months)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Group B (DDFS event >12 months)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Overall comparison between groups A and B
Number of subjects: 404
Study: 34006328

Group type: EXPERIMENTAL
Intervention: Daily tablet PrEP
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: PrEP injection or implant
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Military provider
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Smartphone/telehealth visit
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: On-base locations for lab evaluation and medication pick-up
Number of subjects: 429
Study: 32129892

Group type: EXPERIMENTAL
Intervention: Immunosuppressant (IS) dose reduction
Number of subjects: 283
Study: 32881839

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (14.4% O2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia
Number of subjects: 20
Study: 35177108

Group type: EXPERIMENTAL
Intervention: OPIOID (hydrocodone/acetaminophen 5/300 mg)
Number of subjects: 3

Group type: COMPARATOR
Intervention: NON‐OPIOID (ibuprofen/acetaminophen 400/500 mg)
Number of subjects: 3
Study: 33895428

Group type: EXPERIMENTAL
Intervention: BEAR‐H1 assisted gait training (BAGT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 32
Study: 32223762

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention over 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving traditional oral health information
Number of subjects: 0
Study: 35146754

Group type: EXPERIMENTAL
Intervention: MotherWise (relationship education and brief case management/coaching program)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 136
Study: 33508778

Group type: EXPERIMENTAL
Intervention: Regular ball warm-up (156 g)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Heavier ball warm-up (171.6 g)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Lighter ball warm-up (140.4 g)
Number of subjects: 13
Study: 33165570

Group type: EXPERIMENTAL
Intervention: Esaxerenone 2.5 mg/day
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Esaxerenone 5 mg/day
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Eplerenone 50 mg/day
Number of subjects: 1001
Study: 32750174

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant (FMT) enema from a donor enriched in Lachnospiraceae and Ruminococcaceae
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 32740676

Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg
Number of subjects: 101

Group type: COMPARATOR
Intervention: Olanzapine 10 mg
Number of subjects: 101
Study: 35576290

Group type: EXPERIMENTAL
Intervention: Short duration steroid therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Long duration steroid therapy
Number of subjects: 150
Study: 33347019

Group type: EXPERIMENTAL
Intervention: Nanocurcumin (160 mg/d)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 56
Study: 34918967

Group type: EXPERIMENTAL
Intervention: Acupuncture and metoclopramide
Number of subjects: 62

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 62
Study: 35704472

Group type: EXPERIMENTAL
Intervention: Inclined group (study)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vertical group (control)
Number of subjects: 30
Study: 34682512

Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham mask (control)
Number of subjects: 26
Study: 33893252

Group type: EXPERIMENTAL
Intervention: Gum Arabic mouthwash (G1)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Licorice mouthwash (G2)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash (G3)
Number of subjects: 63
Study: 35986478

Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF) with Glass Ionomer Cement (GIC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF) with Resin‐modified Bioactive Resin (ACTIVA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF) with Composite Resin (CR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Sound dentine without SDF)
Number of subjects: 30
Study: 32791940

Group type: EXPERIMENTAL
Intervention: Prior antiplatelet therapy
Number of subjects: 3154

Group type: COMPARATOR
Intervention: No prior antiplatelet therapy
Number of subjects: 3154
Study: 34799433

Group type: EXPERIMENTAL
Intervention: Filtered cigarettes
Number of subjects: 43

Group type: COMPARATOR
Intervention: Unfiltered cigarettes
Number of subjects: 43
Study: 33530919

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Levobupivacaine
Number of subjects: 40
Study: 32692952

Group type: EXPERIMENTAL
Intervention: ACLC patch
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oblique brace
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Anterior brace
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ACLC patch, oblique brace, anterior brace
Number of subjects: 28
Study: 36257847

Group type: EXPERIMENTAL
Intervention: Colostomy closure without mechanical bowel preparation (MBP)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Colostomy closure with mechanical bowel preparation (MBP)
Number of subjects: 79
Study: 35681510

Group type: COMPARATOR
Intervention: Systemic heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation
Number of subjects: 0
Study: 32089506

Group type: EXPERIMENTAL
Intervention: Percutaneous axillary access with vessel closure device
Number of subjects: 59
Study: 35033226

Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg intravenously every 4 weeks for a maximum of 13 cycles) plus tremelimumab (75 mg intravenously every 4 weeks for a maximum of four cycles) alone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Durvalumab (1500 mg intravenously every 4 weeks for a maximum of 13 cycles) plus tremelimumab (75 mg intravenously every 4 weeks for a maximum of four cycles) with low-dose radiotherapy (0.5 Gy delivered twice per day for 2 days during each of the first four cycles)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Durvalumab (1500 mg intravenously every 4 weeks for a maximum of 13 cycles) plus tremelimumab (75 mg intravenously every 4 weeks for a maximum of four cycles) with hypofractionated radiotherapy (24 Gy total delivered over three 8-Gy fractions during the first cycle only)
Number of subjects: 90
Study: 34328482

Group type: COMPARATOR
Intervention: Semilunar coronally positioned flap (SCPF) alone (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Semilunar coronally positioned flap with free gingival graft (SCPF+FGG) (test)
Number of subjects: 20
Study: 33272839

Group type: EXPERIMENTAL
Intervention: Speech therapy (four-week sessions over one month)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual follow-up (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Speech therapy
Number of subjects: 30
Study: 32081088

Group type: COMPARATOR
Intervention: Usual care questionnaires
Number of subjects: 80

Group type: COMPARATOR
Intervention: Focus groups with healthcare professionals
Number of subjects: 80

Group type: COMPARATOR
Intervention: Case note reviews
Number of subjects: 80

Group type: COMPARATOR
Intervention: Triangulation of findings
Number of subjects: 80
Study: 34865686

Group type: EXPERIMENTAL
Intervention: Binary dance rhythm (12 weeks, twice a week, 45 minutes)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Quaternary dance rhythm (12 weeks, twice a week, 45 minutes)
Number of subjects: 31
Study: 33076997

Group type: EXPERIMENTAL
Intervention: STRIDE mobility program implementation
Number of subjects: 8
Study: 35172810

Group type: EXPERIMENTAL
Intervention: Conventional laparoscopic needle driver
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FlexDex needle driver
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Da Vinci Si surgical system
Number of subjects: 10

Group type: COMPARATOR
Intervention: FlexDex
Number of subjects: 10

Group type: COMPARATOR
Intervention: Laparoscopic and Da Vinci Si
Number of subjects: 10
Study: 33625574

Group type: EXPERIMENTAL
Intervention: Direct Anterior approach (DA group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Posterolateral approach (PL group)
Number of subjects: 44
Study: 32131964

Group type: EXPERIMENTAL
Intervention: Brief behavioural intervention (two sessions: 5 minutes of structured advice and 15-20 minutes of behaviour change counselling, plus an optional booster session)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Brief behavioural intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard preoperative care
Number of subjects: 68
Study: 34800427

Group type: EXPERIMENTAL
Intervention: Aspirin (150 mg once per day until discharge)
Number of subjects: 7351

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 7351

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 7351
Study: 34027922

Group type: EXPERIMENTAL
Intervention: Progressed Plyometric Training (PPT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Non-Progressed Plyometric Training (NPPT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 22
Study: 35947940

Group type: EXPERIMENTAL
Intervention: Contingency awareness questionnaire for neurofeedback
Number of subjects: 20

Group type: COMPARATOR
Intervention: Double-blinded group assignment
Number of subjects: 20
Study: 33283377

Group type: EXPERIMENTAL
Intervention: Real-world cohort of VKA-treated AF patients with CKD
Number of subjects: 1108

Group type: COMPARATOR
Intervention: AMADEUS trial cohort of VKA-treated AF patients with CKD
Number of subjects: 1108
Study: 35410693

Group type: EXPERIMENTAL
Intervention: NETOIMS
Number of subjects: 77

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia
Number of subjects: 77
Study: 34460181

Group type: EXPERIMENTAL
Intervention: Adding SGLT2 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Switching to GLP-1 receptor agonists (GLP-1 RAs)
Number of subjects: 0
Study: 36204125

Group type: EXPERIMENTAL
Intervention: Low-dose NW Low-Glu® (4 capsules per day)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: High-dose NW Low-Glu® (5 capsules per day)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Metformin (2000 mg per day)
Number of subjects: 232
Study: 33337815

Group type: EXPERIMENTAL
Intervention: EtaBS (Enerceptan) 50 mg weekly for 32 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Etanercept 50 mg weekly for 32 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: EtaBS
Number of subjects: 150

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 150
Study: 36383487

Group type: EXPERIMENTAL
Intervention: Collaborative care (support from nonphysician care coordinators, electronic registers, and specialist‐supported case review) for 12 months, followed by 12 months of usual care or 24 months of usual care.
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Collaborative care integrated in clinical workflows.
Number of subjects: 404

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 404
Study: 34142415

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33136471

Group type: EXPERIMENTAL
Intervention: Irinotecan (60 mg/m2, days 1, 8, 15) plus cisplatin (60 mg/m2, day 1)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Etoposide (100 mg/m2, days 1‐3) plus cisplatin (80 mg/m2, day 1)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Etoposide plus cisplatin
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin
Number of subjects: 221
Study: 35368946

Group type: EXPERIMENTAL
Intervention: Yiqi Yangyin Decoction combined with docetaxel
Number of subjects: 92

Group type: COMPARATOR
Intervention: Basic chemotherapy combined with docetaxel
Number of subjects: 92
Study: 34791970

Group type: EXPERIMENTAL
Intervention: NZBC extract (210 mg of anthocyanins) for 7 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NZBC extract (210 mg of anthocyanins) for 14 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NZBC extract (210 mg of anthocyanins) for 7 days during walking
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NZBC extract (210 mg of anthocyanins) for 14 days during walking
Number of subjects: 15
Study: 32112999

Group type: EXPERIMENTAL
Intervention: Topical lidocaine-prilocaine cream
Number of subjects: 190

Group type: COMPARATOR
Intervention: Rectal meloxicam suppository 15 mg
Number of subjects: 190
Study: 35455529

Group type: EXPERIMENTAL
Intervention: Occupational therapy via telerehabilitation (5 sessions per week, 1 hour each for 3 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study: 32030559

Group type: EXPERIMENTAL
Intervention: 370 MBq of 99mTc‐TRODAT‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 740 MBq of 99mTc‐TRODAT‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1110 MBq of 99mTc‐TRODAT‐1
Number of subjects: 30
Study: 34237746

Group type: EXPERIMENTAL
Intervention: Shopping Exercise (SE)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Brandt-Daroff (BD) exercise
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240
Study: 34872405

Group type: EXPERIMENTAL
Intervention: Active iTBS (n=19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham treatment (n=21)
Number of subjects: 40
Study: 32410198

Group type: EXPERIMENTAL
Intervention: Camouflage of the dorsum by diced cartilage
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Camouflage of the dorsum with lipofilling
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Camouflage of the dorsum by a temporal fascia graft
Number of subjects: 101

Group type: COMPARATOR
Intervention: Without camouflage of the dorsum (control group)
Number of subjects: 101
Study: 32598752

Group type: EXPERIMENTAL
Intervention: rabeprazole 40 mg
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: rabeprazole 20 mg
Number of subjects: 89

Group type: COMPARATOR
Intervention: standard dose rabeprazole
Number of subjects: 89

Group type: COMPARATOR
Intervention: CYP2C19 metabolizers (ultrarapid, rapid, normal, intermediate)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: IL‐1β CC genotype
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: MDR1 TT genotype
Number of subjects: 89
Study: 34767728

Group type: EXPERIMENTAL
Intervention: Supportive interpersonal relationships (siblings, grandparents, teachers, friends' parents)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Discouragement from conflicting rules and social comparison
Number of subjects: 33
Study: 34963300

Group type: EXPERIMENTAL
Intervention: Target LDL cholesterol of <70 mg/dL
Number of subjects: 2860

Group type: COMPARATOR
Intervention: Target LDL cholesterol of 100±10 mg/dL
Number of subjects: 2860
Study: 35543211

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention (MBI) for 8 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention (MBI)
Number of subjects: 19
Study: 32510573

Group type: EXPERIMENTAL
Intervention: HidroQoL© intervention
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 171
Study: 33107841

Group type: EXPERIMENTAL
Intervention: Intensive term-time workers (female)
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Moderate term-time workers
Number of subjects: 2800

Group type: COMPARATOR
Intervention: Non term-time workers (female)
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Term-time workers (13-15 years old)
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Term-time workers (financially well-off families)
Number of subjects: 2800
Study: 34623761

Group type: EXPERIMENTAL
Intervention: Three doses of perioperative antibiotics (piperacillin + tazobactam - 4.5 g intravenous at fixed 8 hourly intervals)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Nine doses of perioperative antibiotics (piperacillin + tazobactam - 4.5 g intravenous at fixed 8 hourly intervals)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Three doses of perioperative antibiotics
Number of subjects: 126

Group type: COMPARATOR
Intervention: Nine doses of perioperative antibiotics
Number of subjects: 126
Study: 34350669

Group type: EXPERIMENTAL
Intervention: Adapted mental health experience codesign intervention
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control phase
Number of subjects: 287
Study: 32543979

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 0
Study: 35577410

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 4 months
Number of subjects: 193

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 193
Study: 32907392

Group type: EXPERIMENTAL
Intervention: Domiciliary program of oculomotor and gaze stability exercises for three weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (standard rehabilitation program)
Number of subjects: 68
Study: 34492326

Group type: EXPERIMENTAL
Intervention: Sterile gloves (modified sterile technique: only sterile gloves)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Clean technique (usual care with non-sterile gloves)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Baseline period (before intervention)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Intervention period (after intervention)
Number of subjects: 530
Study: 33491287

Group type: EXPERIMENTAL
Intervention: Green tea (GT) and resistance training (RT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 44
Study: 35439530

Group type: EXPERIMENTAL
Intervention: Sacrospinous hysteropexy
Number of subjects: 207

Group type: COMPARATOR
Intervention: Vaginal hysterectomy with uterosacral ligament suspension
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Preoperative Pelvic Organ Prolapse Quantification stage 3 or 4
Number of subjects: 207